Clinical Trials List
2015-11-01 - 2026-12-31
Phase III
Terminated5
ICD-10C61
Malignant neoplasm of prostate
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- CHUNG-HSIN CHEN Division of Urology
- - - Division of Urology
- Chia-Hsien Chen Division of Radiology
- CHING-CHU LU Division of Nuclear Medicine
- Hong-Chiang Chang Division of Urology
- 戴槐青 Division of Urology
- 劉詩彬 Division of Urology
- - - Division of Urology
- YEN-HENG LIN Division of Radiology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
- 裘坤元 Division of Urology
- 熊小澐 Division of Radiology
- 蔡世傳 Division of Nuclear Medicine
- Shian-Shiang Wang Division of Urology
- Cheng-Kuang Yang Division of Urology
- Chuan-Shu Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wen-Chi Chen Division of Urology
- Chi-Rei Yang Division of Urology
- Yi-Huei Chang Division of Urology
- Chao-Hsiang Chang Division of Urology
- 陳冠亨 Division of Urology
- Chi-Ping Huang Division of Urology
- Po-Fan Hsieh Division of Urology
- Chin-Chung Yeh Division of Urology
- Chi-Shun Lien Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Tsung-Yi Huang Division of Urology
- 黃俊農 Division of Urology
- Hsiang Ying Lee Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
Audit
None
Taiwan National PI
Co-Principal Investigator
- See-Tong Pang Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- 范綱行 Division of Radiation Therapy
- 張英勛 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
1 Stop recruiting
Audit
None
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
75 participants
-
Global
1860 participants
